Nonseminomatous Germ Cell Tumor disease: Malacards - Research Articles, Drugs, Genes, Clinical Trials

NSGCT MCID: NNS011 MIFTS: 26	Nonseminomatous Germ Cell Tumor (NSGCT) Categories: Rare diseases	Data Licensing For inquiries, contact: [email protected]
Genes Variations Tissues Related diseases Publications Drugs Expand all tables

Sources

Aliases & Classifications for Nonseminomatous Germ Cell Tumor

MalaCards integrated aliases for Nonseminomatous Germ Cell Tumor:

Name: Nonseminomatous Germ Cell Tumor ¹⁹ ⁷¹

Non-Seminomatous Germ-Cell Tumors ¹⁹

Germ Cell Tumor, Nonseminomatous ⁵

Nsgct ¹⁹

Classifications:

MalaCards categories:
Global: Rare diseases

See all MalaCards categories (disease lists)

External Ids:

UMLS ⁷¹ C1266158

Sources

Summaries for Nonseminomatous Germ Cell Tumor

GARD: ¹⁹ Nonseminomatous germ cell tumors are cancerous tumors commonly found in the pineal gland in the brain, in the mediastinum, or in the abdomen. They originate from cells that were meant to form sex cells (i.e., sperm or eggs). They are often large and have a tendency to spread more quickly than the other type of germ cell tumor (i.e., seminoma type). Possible early signs of this cancer include chest pain and breathing problems.

MalaCards based summary: Nonseminomatous Germ Cell Tumor, also known as non-seminomatous germ-cell tumors, is related to extragonadal nonseminomatous germ cell tumor and testicular germ cell tumor. An important gene associated with Nonseminomatous Germ Cell Tumor is BRAF (B-Raf Proto-Oncogene, Serine/Threonine Kinase). The drugs Cisplatin and Bleomycin have been mentioned in the context of this disorder. Affiliated tissues include pineal, brain and lymph node.

Sources

Related Diseases for Nonseminomatous Germ Cell Tumor

Diseases related to Nonseminomatous Germ Cell Tumor via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 77)

#	Related Disease	Score
1	extragonadal nonseminomatous germ cell tumor	11.6
2	testicular germ cell tumor	11.5
3	germ cell tumor	11.2
4	teratoma	10.9
5	testicular cancer	10.8
6	mature teratoma	10.7
7	embryonal carcinoma	10.6
8	germ cell cancer	10.6
9	testicular germ cell cancer	10.5
10	malignant teratoma	10.5
11	growing teratoma syndrome	10.5
12	endodermal sinus tumor	10.5
13	teratocarcinoma	10.4
14	choriocarcinoma	10.4
15	ewing sarcoma	10.4
16	mixed germ cell cancer	10.4
17	seminoma	10.4
18	mediastinal cancer	10.4
19	tatton-brown-rahman syndrome	10.3
20	respiratory failure	10.3
21	prostate cancer	10.3
22	factor vii deficiency	10.3
23	trophoblastic neoplasm	10.3
24	lymphocele	10.3
25	lung cancer	10.2
26	graves disease 1	10.2
27	mucositis	10.2
28	adult respiratory distress syndrome	10.2
29	mixed cell type cancer	10.2
30	pigmented villonodular synovitis	10.2
31	glomerulonephritis	10.2
32	tenosynovial giant cell tumor	10.2
33	pancreatic adenocarcinoma	10.2
34	liver disease	10.2
35	extragonadal germ cell cancer	10.2
36	testicular yolk sac tumor	10.2
37	spermatocytoma	10.2
38	chronic kidney disease	10.2
39	hyperthyroidism	10.2
40	renal cell carcinoma, nonpapillary	10.1
41	sarcoidosis 1	10.1
42	renal hypodysplasia/aplasia 1	10.1
43	ascites, chylous	10.1
44	chondrosarcoma	10.1
45	rhabdomyosarcoma 2	10.1
46	testicular germ cell tumor 1	10.1
47	stroke, ischemic	10.1
48	spastic paraplegia, ataxia, and mental retardation	10.1
49	sarcoidosis 2	10.1
50	sarcoidosis 3	10.1

Graphical network of the top 20 diseases related to Nonseminomatous Germ Cell Tumor:

Sources

Symptoms & Phenotypes for Nonseminomatous Germ Cell Tumor

Sources

Drugs & Therapeutics for Nonseminomatous Germ Cell Tumor

Drugs for Nonseminomatous Germ Cell Tumor (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show all 30)

Name

Status

Phase

Clinical Trials

Cas Number

PubChem Id

Cisplatin

Approved

Phase 3

15663-27-1

2767 5702198 441203

Bleomycin

Approved, Investigational

Phase 3

9041-93-4, 11056-06-7

5360373

Etoposide

Approved

Phase 3

33419-42-0

36462

Paclitaxel

Approved, Vet_approved

Phase 3

33069-62-4

36314

Ifosfamide

Approved

Phase 3

3778-73-2

3690

Oxaliplatin

Approved, Investigational

Phase 3

61825-94-3

43805 11947679 6857599

Palifosfamide

Investigational

Phase 3

31645-39-3

100427

Alkylating Agents

Phase 3

Antineoplastic Agents, Alkylating

Phase 3

Anti-Bacterial Agents

Phase 3

Albumin-Bound Paclitaxel

Phase 3

Etoposide phosphate

Phase 3

16760419

Antimitotic Agents

Phase 3

Tubulin Modulators

Phase 3

Antibiotics, Antitubercular

Phase 3

Gemcitabine

Approved

Phase 2

95058-81-4, 122111-03-9

60750

Mechlorethamine

Approved, Investigational

Phase 2

51-75-2

4033

Durvalumab

Approved, Investigational

Phase 2

1428935-60-7

Tremelimumab

Approved, Investigational

Phase 2

745013-59-6

Fludarabine

Approved

Phase 2

75607-67-9, 21679-14-1

30751 657237

Cyclophosphamide

Approved, Investigational

Phase 2

50-18-0, 6055-19-2

2907

Brentuximab vedotin

Approved, Investigational

Phase 2

914088-09-8

Pembrolizumab

Approved

Phase 2

1374853-91-4

254741536

Antiviral Agents

Phase 2

Anti-Infective Agents

Phase 2

Antimetabolites

Phase 2

Antirheumatic Agents

Phase 2

Immunosuppressive Agents

Phase 2

Immunologic Factors

Phase 2

Antineoplastic Agents, Immunological

Phase 2

Interventional clinical trials:

(show all 13)

#	Name	Status	NCT ID	Phase	Drugs
1	A Risk-Adapted Strategy of the Use of Dose-Dense Chemotherapy in Patients With Poor-Prognosis Disseminated Non-Seminomatous Germ Cell Tumors	Active, not recruiting	NCT00104676	Phase 3	cisplatin;etoposide;ifosfamide;oxaliplatin;paclitaxel
2	A Prospective Phase II Trial of Cabazitaxel in Male Patients With Chemotherapy Pre-treated Metastatic Nonseminomatous Germ-cell Tumors	Unknown status	NCT02115165	Phase 2	Cabazitaxel
3	A Prospective Multicenter Phase II Trial of Gemcitabine, Cisplatin, and Ifosfamide (GIP) in Patients With Relapsed Non-Seminomatous Germ-Cell Tumors (NSGCT) and a Predicted Favorable Prognosis	Unknown status	NCT00127049	Phase 2	gemcitabine, ifosfamide, cisplatin, G-CSF
4	A Prospective,Multicenter, Phase II Study to Evaluate the Contribution of the Imaging TEP to the Expression of intégrines αvβ3 for the Characterization of the Residual Masses of Non-seminoma Tumors at the End of Chemotherapy	Completed	NCT02317393	Phase 2
5	A Treatment Strategy of the Use of 1st Line Chemotherapy in Patients With Poor-Prognosis Disseminated Non-Seminomatous Germ Cell Tumors Based on Tumor Marker Decline: A Phase II Trial of Paclitaxel, Ifosfamid and Cisplatin Regimen.	Completed	NCT02414685	Phase 2	Paclitaxel;Ifosfamide;Cisplatin
6	A Single-arm, Phase II Study of Durvalumab (MEDI4736) and Tremelimumab for Relapsed/Refractory Germ Cell Tumors	Active, not recruiting	NCT03158064	Phase 2	Durvalumab;Tremelimumab
7	Administration of T Lymphocytes Expressing the CD30 Chimeric Antigen Receptor (CAR) for Patients With CD30+ Nonseminomatous Germ Cell Tumors (NSGCT)	Not yet recruiting	NCT05634785	Phase 2	Cyclophosphamid;Fludarabine
8	Randomized Phase II Trial Evaluating Compliance With Monitoring Conducted Either by a Hospital-based Physician in Person or by a Nurse in Remote Monitoring	Not yet recruiting	NCT05500391	Phase 2
9	A Multicenter Phase II Study of Brentuximab Vedotin in Relapsed/Refractory Germ Cell Tumors	Terminated	NCT02689219	Phase 2	Brentuximab Vedotin
10	A Phase II Single-Arm Multi-Center Trial Evaluating the Efficacy of Pembrolizumab in the Treatment of Subjects With Incurable Platinum-Refractory Germ Cell Tumors: Hoosier Cancer Research Network GU14-206	Terminated	NCT02499952	Phase 2	Pembrolizumab
11	Assessment of the Utility of CT Follow Up in the Long Term Follow Up of Patients With Metastatic Non Seminomatous Germ Cell Tumour (NSGCT)	Unknown status	NCT00553371
12	Correlation of Histopathology, Immunohistochemistry and Quantitative Radiology With Outcome in Early Stage Nonseminomatous Germ Cell Tumor	Completed	NCT00003800
13	Improving Adolescent and Young Adult Self-Reported Data in ECOG-ACRIN Trials	Recruiting	NCT05108298	Early Phase 1

Search NIH Clinical Center for Nonseminomatous Germ Cell Tumor

Sources

Genetic Tests for Nonseminomatous Germ Cell Tumor

Sources

Anatomical Context for Nonseminomatous Germ Cell Tumor

Organs/tissues related to Nonseminomatous Germ Cell Tumor:

MalaCards : Pineal, Brain, Lymph Node, Testis, Bone Marrow, Testes, Thyroid

Sources

Publications for Nonseminomatous Germ Cell Tumor

Articles related to Nonseminomatous Germ Cell Tumor:

(show top 50) (show all 1130)

#	Title	Authors	PMID	Year
1	Codon-specific translation reprogramming promotes resistance to targeted therapy. ⁵	Rapino F...Close P	29925953	2018
2	A somatic mutation in erythro-myeloid progenitors causes neurodegenerative disease. ⁵	Mass E...Geissmann F	28854169	2017
3	eIF4F is a nexus of resistance to anti-BRAF and anti-MEK cancer therapies. ⁵	Boussemart L...Vagner S	25079330	2014
4	Copper is required for oncogenic BRAF signalling and tumorigenesis. ⁵	Brady DC...Counter CM	24717435	2014
5	Reversible and adaptive resistance to BRAF(V600E) inhibition in melanoma. ⁵	Sun C...Bernards R	24670642	2014
6	Germline mutations in oncogene-induced senescence pathways are associated with multiple sessile serrated adenomas. ⁵	Gala MK...Chung DC	24512911	2014
7	A key role for mitochondrial gatekeeper pyruvate dehydrogenase in oncogene-induced senescence. ⁵	Kaplon J...Peeper DS	23685455	2013
8	Modelling vemurafenib resistance in melanoma reveals a strategy to forestall drug resistance. ⁵	Das Thakur M...Stuart DD	23302800	2013
9	Unresponsiveness of colon cancer to BRAF(V600E) inhibition through feedback activation of EGFR. ⁵	Prahallad A...Bernards R	22281684	2012
10	RAF inhibitor resistance is mediated by dimerization of aberrantly spliced BRAF(V600E). ⁵	Poulikakos PI...Solit DB	22113612	2011
11	Melanomas acquire resistance to B-RAF(V600E) inhibition by RTK or N-RAS upregulation. ⁵	Nazarian R...Lo RS	21107323	2010
12	COT drives resistance to RAF inhibition through MAP kinase pathway reactivation. ⁵	Johannessen CM...Garraway LA	21107320	2010
13	Clinical efficacy of a RAF inhibitor needs broad target blockade in BRAF-mutant melanoma. ⁵	Bollag G...Nolop K	20823850	2010
14	Inhibition of mutated, activated BRAF in metastatic melanoma. ⁵	Flaherty KT...Chapman PB	20818844	2010
15	BRAF mutation in metastatic colorectal cancer. ⁵	Tol J...Punt CJ	19571295	2009
16	BRAF gene duplication constitutes a mechanism of MAPK pathway activation in low-grade astrocytomas. ⁵	Pfister S...Lichter P	18398503	2008
17	Association of BRAF V600E mutation with poor clinicopathological outcomes in 500 consecutive cases of papillary thyroid carcinoma. ⁵	Lupi C...Basolo F	17785355	2007
18	BRAF mutations in papillary thyroid carcinomas inhibit genes involved in iodine metabolism. ⁵	Durante C...Russo D	17488796	2007
19	BRAF V600E maintains proliferation, transformation, and tumorigenicity of BRAF-mutant papillary thyroid cancer cells. ⁵	Liu D...Xing M	17374713	2007
20	Influence of the BRAF V600E mutation on expression of vascular endothelial growth factor in papillary thyroid cancer. ⁵	Jo YS...Shong M	16772349	2006
21	BRAF mutation predicts a poorer clinical prognosis for papillary thyroid cancer. ⁵	Xing M...Ladenson PW	16174717	2005
22	High prevalence and possible de novo formation of BRAF mutation in metastasized papillary thyroid cancer in lymph nodes. ⁵	Vasko V...Xing M	15998781	2005
23	BRAF mutations in colorectal carcinoma suggest two entities of microsatellite-unstable tumors. ⁵	Lubomierski N...Raedle J	16015629	2005
24	High incidence of thyroid cancer in long-standing goiters with thyroglobulin mutations. ⁵	Hishinuma A...Ieiri T	16187918	2005
25	Silencing of the tumor suppressor gene SLC5A8 is associated with BRAF mutations in classical papillary thyroid carcinomas. ⁵	Porra V...Rousset B	15687339	2005
26	Mutations of BRAF and RAS are rare events in germ cell tumours. ⁵	Sommerer F...Tannapfel A	15386408	2005
27	BRAF screening as a low-cost effective strategy for simplifying HNPCC genetic testing. ⁵	Domingo E...Schwartz S	15342696	2004
28	Low frequency of BRAFT1796A mutations in childhood thyroid carcinomas. ⁵	Kumagai A...Yamashita S	15356022	2004
29	Detection of BRAF mutation on fine needle aspiration biopsy specimens: a new diagnostic tool for papillary thyroid cancer. ⁵	Xing M...Ladenson PW	15181070	2004
30	BRAF(V599E) mutation is the leading genetic event in adult sporadic papillary thyroid carcinomas. ⁵	Puxeddu E...Santeusanio F	15126572	2004
31	BRAF T1796A transversion mutation in various thyroid neoplasms. ⁵	Xing M...Sidransky D	15001635	2004
32	Mutational analysis of BRAF and K-ras in gastric cancers: absence of BRAF mutations in gastric cancers. ⁵	Kim IJ...Park JG	14513361	2003
33	BRAF mutations in thyroid tumors are restricted to papillary carcinomas and anaplastic or poorly differentiated carcinomas arising from papillary carcinomas. ⁵	Nikiforova MN...Nikiforov YE	14602780	2003
34	Exclusion of BRAFV599E as a melanoma susceptibility mutation. ⁵	Meyer P...Garbe C	12794760	2003
35	BRAF mutations in metastatic melanoma: a possible association with clinical outcome. ⁵	Kumar R...Hemminki K	12960123	2003
36	High prevalence of BRAF mutations in thyroid cancer: genetic evidence for constitutive activation of the RET/PTC-RAS-BRAF signaling pathway in papillary thyroid carcinoma. ⁵	Kimura ET...Fagin JA	12670889	2003
37	Mutations in BRAF and KRAS characterize the development of low-grade ovarian serous carcinoma. ⁵	Singer G...Shih IeM	12644542	2003
38	Absence of exon 15 BRAF germline mutations in familial melanoma. ⁵	Lang J...MacKie R	12619120	2003
39	High frequency of BRAF mutations in nevi. ⁵	Pollock PM...Meltzer PS	12447372	2003
40	Tumorigenesis: RAF/RAS oncogenes and mismatch-repair status. ⁵	Rajagopalan H...Velculescu VE	12198537	2002
41	Mutations of the BRAF gene in human cancer. ⁵	Davies H...Futreal PA	12068308	2002
42	Role of Lactate Dehydrogenase in Identifying Relapse for Patients With Stage I Testicular Cancer on Surveillance. ⁶²	Bobrowski A...Hamilton RJ	35997696	2022
43	French AFU Cancer Committee Guidelines - Update 2022-2024: testicular germ cell cancer. ⁶²	Murez T...Roupret M	36400478	2022
44	Primary Retroperitoneal Lymph Node Dissection for Patients With Pathologic Stage II Nonseminomatous Germ Cell Tumor-N1, N2, and N3 Disease: Is Adjuvant Chemotherapy Necessary? ⁶²	Tachibana I...Cary C	35675585	2022
45	A comprehensive evaluation of sexual and reproductive outcomes following robot-assisted retroperitoneal lymph node dissection for nonseminomatous germ cell tumor. ⁶²	Mistretta FA...Musi G	35381697	2022
46	Treatment Outcomes for Men with Clinical Stage II Nonseminomatous Germ Cell Tumours Treated with Primary Retroperitoneal Lymph Node Dissection: A Systematic Review. ⁶²	Neuenschwander A...Fankhauser CD	36379869	2022
47	Extracranial germ cell tumours in children and adolescents: Results from the French TGM13 protocol. ⁶²	Conter CF...Chabaud S	36451268	2022
48	Reply to Alireza Ghoreifi and Hooman Djaladat's Letter to the Editor re: Isamu Tachibana, Sean Q. Kern, Antoin Douglawi, et al. Primary Retroperitoneal Lymph Node Dissection for Patients with Pathologic Stage II Nonseminomatous Germ Cell Tumor-N1, N2, and N3 Disease: Is Adjuvant Chemotherapy Necessary? J Clin Oncol. In press. https://doi.org/10.1200/JCO.22.00118: Is Retroperitoneal Lymph Node Dissection Without Adjuvant Chemotherapy Enough for All Patients with Pathologic Stage II Nonseminoma Germ Cell Tumor? ⁶²	Tachibana I...Cary C	36195478	2022
49	Re: Isamu Tachibana, Sean Q. Kern, Antoin Douglawi, et al. Primary Retroperitoneal Lymph Node Dissection for Patients with Pathologic Stage II Nonseminomatous Germ Cell Tumor-N1, N2, and N3 Disease: Is Adjuvant Chemotherapy Necessary? J Clin Oncol. In press. https://doi.org/10.1200/JCO.22.00118: Is Retroperitoneal Lymph Node Dissection Without Adjuvant Chemotherapy Enough for All Patients with Pathologic Stage II Nonseminoma Germ Cell Tumor? ⁶²	Ghoreifi A...Djaladat H	36195480	2022
50	Accuracy of germ cell tumor histology and stage within a Canadian cancer registry. ⁶²	Holland P...Wood LA	36218319	2022

Sources

Genes for Nonseminomatous Germ Cell Tumor

Genes related to Nonseminomatous Germ Cell Tumor (1 elite genes):

- Elite gene

- Cancer Census gene in COSMIC

#	Symbol	Description	Category	Score	Evidence	PubMed IDs
1	BRAF	B-Raf Proto-Oncogene, Serine/Threonine Kinase	Protein Coding	400	Pathogenic ⁵	12960123 12068308 12447372 (more) 12619120 12794760 14513361 12198537 12644542 20818844 20823850 21107320 21107323 22113612 23302800 23685455 24670642 25079330 15342696 16015629 19571295 22281684 24512911 12670889 15001635 14602780 15356022 15126572 15181070 16174717 15687339 15998781 16187918 17374713 16772349 17488796 17785355 15386408 18398503 28854169 24717435 29925953